The FDA’s new PreCheck programme is aimed at facilitating the introduction of new US drug manufacturing facilities.

CorMedix, a biopharmaceutical company specialising in critical care products, is to acquire Melinta Therapeutics for $300m.

Primary packaging is never an afterthought in the world of injectable drugs, where systems such as vials, syringes, and ...

The US Food and Drug Administration (FDA) has lifted a pause in the use of Valneva’s chikungunya vaccine Ixchiq in older adults after a benefit-risk reevaluation, though the move comes with an ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

The Gates Foundation has announced an investment of $2.5bn to 2030, dedicated to expediting R&D with a focus on improving women's health.

Linked data could unlock essential hidden insights across healthcare – but linking has to be executed correctly to avoid ...

The upcoming EpiPen patent expiration on 11 September 2025 sets the stage for a pivotal shift in the epinephrine delivery market.

The health secretary has halted the development of 22 mRNA vaccine projects by BARDA while stopping all future schemes.

Spanning topics across R&D, clinical trials, and commercial launch, our podcast series continues as two clinical supplies ...

Genmab and AbbVie’s Epkinly has met its dual primary endpoints as a second-line combination therapy in relapsed/refractory follicular lymphoma (FL).

Astria has made an exclusive licensing agreement with Kaken for the development and commercialisation rights of navenibart in Japan.